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Abstract
Background: Hypothyroidism (HO) can significantly impair lipid metabolism and increase cardiovascular disease
risk. Hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular disease. Our previous study
demonstrated that HHcy significantly induced insulin resistance and impaired coronary artery endothelial function
in patients with either hypertension or HO. In the present study, we studied whether plasma levels of high-density
lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (Apo A-I) were altered in patients with HO, and if so, whether
this change was mediated by HHcy.
Methods: A total of 258 subjects were enrolled and divided into the following three groups: control group (n = 94),
HO group (n = 73), and subclinical hypothyroidism (SHO) group (n = 91). Additionally, all groups were subdivided based
on the subjects’ Hcy levels into HHcy (plasma Hcy level over 15 μmol/l) and normal Hcy subgroups. The plasma levels
of lipid indexes were measured. Statistical analyses were performed to evaluate the correlations between groups.
Results: The plasma Hcy levels were significantly higher in the HO group than in the SHO or control groups (all p < 0.05).
Moreover, levels of Apo A-I and HDL-C were markedly reduced in the HHcy subgroup compared with the normal Hcy
subgroup for patients with either HO (Apo A-I: p < 0.05; HDL-C: p < 0.01) or SHO (Apo A-I: p < 0.05; HDL-C: p < 0.01). In
addition, the plasma Hcy levels were negatively correlated with levels of Apo A-I in all three groups (HO group: r = − 0.
320, SHO group: r = − 0.337 and control group: r = − 0.317; all p < 0.01).
Conclusions: Hcy levels were significantly increased in patients with HO or SHO. These increased Hcy levels may impair
cardiovascular function via the inhibition of Apo A-1 expression and impairment of its antioxidant capacity. Our findings
provide new insights into the pathogenesis of hypothyroidism-induced metabolic disorders.
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Background
Hypothyroidism (HO) and subclinical hypothyroidism
(SHO), the two most common endocrine disorders, can
induce metabolic dysfunction [1] and increase the risk of
cardiovascular disease [2, 3]. In patients with HO or
SHO, dyslipidemia may account for the high risk of
cardiovascular disease, including elevated levels of total
cholesterol (CHOL), low-density lipoprotein cholesterol
(LDL-C) and triglycerides (TG) [4, 5]. The major role of
high-density lipoprotein cholesterol (HDL-C) is reverse
cholesterol transport, in which cholesterol from the
peripheral tissue and vessel wall can be transported to
the liver. HDL-C exerts anti-inflammatory, antioxidant,
anticoagulant, and profibrinolytic activities that may
further protect against cardiovascular disease [6]. The
relationship between coronary artery disease and low
levels of plasma HDL-C have been demonstrated in earlier
studies [7, 8]. Apolipoprotein A-I (Apo A-I) is the major
protein component of HDL-C and exerts anti-atherogenic
effects via several mechanisms, including reverse choles-
terol transport [9, 10]. Reduced HDL-C and Apo A-I
levels increase the risk of cardiovascular disease.
Homocysteine (Hcy) levels are increased in patients
with HO or SHO [11, 12], and Hcy is associated with
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the severity of lipid metabolism dysfunction. Hyperho-
mocysteinemia (HHcy) is an independent risk factor for
atherosclerosis [13, 14]. Our previous study demonstrated
that HHcy induced insulin resistance in patients with HO
or SHO [15] and impaired coronary artery endothelial func-
tion in patients with hypertension or hypertriglyceridemia
[16, 17]. Several studies have reported a negative association
between levels of Hcy and Apo A-I and both cardiovascular
events and atherosclerosis disease [18–20]. Thyroid hor-
mones affect reverse cholesterol transport by increasing the
activity of hepatic lipase and cholesteryl ester transfer pro-
tein (CETP), and these changes may result in HDL-C and
Apo A- I being increased in HO. With increasing Hcy
levels, however, some Hcy molecules are converted to
homocysteine thiolactone (HcyT), which forms an iso-
peptide bond with the lysine residues of proteins; this
process is known as N-homocysteinylation [21]. A
recent study found that N-homocysteinylation of Apo
A-I impairs its antioxidant ability [22]. However, associa-
tions between Hcy and Apo A- I levels have not been well
characterized. In this present study, we tested for potential
associations between levels of Hcy and Apo A-I that could
help explain the increased risk of arteriosclerotic coronary
artery disease associated with HO and SHO.
Methods
Subjects
This study initially enrolled 236 outpatients and was
conducted from January to December 2013 at the
Department of Endocrinology in Beijing Chaoyang Hos-
pital. HO is a thyroid hormone deficiency and can develop
as a primary disease of the thyroid gland itself. An elevated
thyrotropin (TSH) level, usually above 10 μIU/ml, along
with a subnormal free thyroxine (FT4) level, characterizes
overt HO [23]. SHO is defined as a serum TSH concentra-
tion above the statistically defined upper limit of the refer-
ence range and when serum FT4 and free triiodothyronine
(FT3) concentrations are within the normal reference
ranges [24, 25]. This designation is only applicable when
thyroid function has been stable for several weeks, the
hypothalamic–pituitary–thyroid axis is normal, and there is
no recent or ongoing severe illness. Exclusion criteria were
as follows: patients with cardiovascular disease, hyperten-
sion, diabetes mellitus or impaired glucose tolerance, renal
diseases or other endocrine diseases. Therefore, 72 patients
were excluded. The final study cohort consisted of 164 pa-
tients among those individuals who were initially enrolled,
including 73 and 91 patients with HO and SHO, respect-
ively. None of the patients received any treatment. The
control group included 94 normal, non-HO volunteers who
were seeking routine medical care at the physical examin-
ation centre of Beijing Chaoyang Hospital.
HHcy was defined as a plasma Hcy level greater than
15 μmol/l [17]. Based on the presence of HHcy, each
group was subdivided into two subgroups. The normal ref-
erence value of Hcy was less than 15 μmol/L. In the HO
group, the patients with a plasma level of Hcy > 15 μmol/l
were termed the H-HO group (n = 36), and the other pa-
tients made up the N-HO group (n = 37). Similarly, we di-
vided the SHO group into the H-SHO (n = 32) and N-SHO
(n = 59) groups, and the control group was split into the H-
control (n = 18) and N-control (n = 76) groups.
Sample collection
Basic demographic data (i.e., age, sex, body height and
weight) were collected from each patient. Subjects wore
only underwear for height and weight measurements,
which were assessed to the nearest 0.5 cm and 0.1 kg,
respectively, by a well-trained examiner. Body mass index
(BMI) was calculated as follows: bodyweight(kg)/[pa-
tient height(m)]2. After overnight fasting, blood sam-
ples were collected from the peripheral vein of each patient
and subjected to a routine analysis that consisted of Hcy,
CHOL, HDL-C,LDL-C, TG, Apo A-I, Apolipoprotein B
(Apo B), FT3, FT4, and TSH measurements.
Measurements of plasma levels of Hcy
Plasma Hcy concentrations were determined using an
enzymatic cycling assay-based quantitative method using
kits from Baiding Biotech (Beijing, China) according to
the manufacturer’s instructions. The normal reference value
was less than 15 μmol/l.
Measurements of blood lipid and thyroid function
indexes
Levels of CHOL, HDL-C, LDL-C, TG, Apo A-I, and
Apo B were determined using a Dade-Behring Dimension
RXL Autoanalyser (Dade Behring Diagnostics, Marburg,
Germany). Reference intervals for CHOL, HDL-C,
LDL-C, TG, Apo A-I and Apo B were 3.62–5.70 mmol/l,
1.03–1.55 mmol/l, 1.81–3.36 mmol/l, 0.56–2.26 mmol/l,
1.00–1.70 g/l, and 0.40–1.20 g/l, respectively.
Levels of FT3, FT4 and TSH were determined by an
electrochemiluminescence immunoassay (ECLIA) using
an Abbott Architect I2000 (Abbott Diagnostics, Abbott
Park, IL, USA). Reference intervals for FT3, FT4, and
TSH were 1.71–3.71 pg/ml, 0.7–1.48 ng/dl and 0.35–
4.94 μIU/ml, respectively.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences software package
(version 17.0, SPSS Inc., Chicago, IL, USA) to identify
significant effects between patient groups and corre-
sponding controls. Because Hcy and TG did not follow
a normal distribution, comparisons between groups were
performed using Mann–Whitney U or Kruskal–Wallis
H tests. Values are expressed as medians (25th and
Yang et al. Lipids in Health and Disease  (2016) 15:123 Page 2 of 7
75th percentiles), and qualitative data are expressed as
means ± standard deviations (SDs). Comparisons among
groups were performed using independent-samples or
one-way ANOVA. Spearman’s rank correlation was used
to test for associations between Hcy and other variables.
All tests were two-tailed, and p-values less than 0.05 were
considered to be significant.
Results
Clinical characteristics of the study subjects
The clinical characteristics and laboratory test findings
of subjects are summarized in Table 1. The incidence of
HO or SHO in females was significantly higher than that
in males. The CHOL, HDL-C, LDL-C, Apo A-I and Apo
B values in the HO group were significantly higher than
those in the SHO and control groups; no differences
were detected between the SHO and control groups
[CHOL: 5.98 ± 1.67 vs. 5.09 ± 1.21 and 5.00 ± 1.00 mmol/l;
HDL-C: 1.62 ± 0.40 vs. 1.47 ± 0.33 and 1.47 ± 0.30 mmol/l;
LDL-C: 3.47± 1.21 vs. 3.03 ± 0.95 and 2.89 ± 0.81 mmol/l;
Apo A-I: 1.49 ± 0.38 vs. 1.34 ± 0.28 and 1.35 ± 0.27 g/l
(Fig. 1); Apo B: 1.01 ± 0.34 vs. 0.92 ± 0.26 and 0.89 ±
0.24 g/l; respectively; all p < 0.05]. A significant increase
in the Hcy levels was observed in patients with HO
compared with those in the SHO and control groups
[15.00 (13.00–21.50) vs. 14.00 (12.00–17.00) vs. 13.00
(10.75–15.00) μmol/l, respectively, all p < 0.05] (Fig. 2).
No significant difference was identified among the three
groups for age, BMI or TG levels.
Subgroup analysis of study participants
The characteristics and blood lipid indexes of the patient
subgroups are summarized in Table 2. Levels of CHOL
were higher in the H-HO group than in the H-SHO and
H-control groups; no difference was detected between
the H-SHO and H-control groups (6.24 ± 2.06 vs. 5.26 ±
1.69 and 5.03 ± 0.90 mmol/l, respectively, p < 0.05). Levels
of Apo A-I were higher in the H-HO than in the H-
control group (1.39 ± 0.35 vs. 1.20 ± 0.17 mmol/l, p <
0.05); no significant differences associated with HHcy
were detected for the other lipid indexes among the three
patient subgroups. The levels of CHOL, HDL-C, LDL-C
and Apo A-I in the N-HO group were significantly higher
than those in the N-SHO and N-control groups; no sig-
nificant differences were detected between the N-SHO
and N-control groups [CHOL: 5.73 ± 1.15 vs. 4.99 ± 0.85
and 4.99 ± 1.03 mmol/l; HDL-C: 1.79 ± 0.34 vs. 1.54 ± 0.32
and 1.48 ± 0.31 mmol/l; LDL-C:3.36 ± 0.94 vs. 2.91 ± 0.72
and 2.87 ± 0.82 mmol/l; Apo A-I: 1.59 ± 0.38 vs. 1.39 ±
0.27 and 1.38 ± 0.28 g/l (Fig. 3); respectively; all p < 0.05].
The levels of HDL-C and Apo A-I were lower in the H-
HO group than in the N-HO group (HDL-C:1.44 ± 0.37
vs. 1.79 ± 0.34 mmol/l, respectively, p < 0.01; Apo A-I:
1.39 ± 0.35 vs. 1.59 ± 0.38 g/l, respectively, p < 0.05). The
levels of HDL-C and Apo A-I were lower in the H-SHO
than in the N-SHO group (HDL-C: 1.35 ± 0.31 vs. 1.54 ±
0.32 mmol/l, respectively, p < 0.01; Apo A-I: 1.25 ± 0.27 vs.
1.39 ± 0.27 g/l, respectively, p < 0.05). Finally, the levels of
Apo A-I were lower in the H-control than in the N-
control group (1.20 ± 0.17 vs. 1.38 ± 0.28 g/l, respectively,
p < 0.05).
Correlation between plasma levels of Hcy and both
thyroid function and blood lipid indexes
Table 3 shows that Hcy was negatively correlated with the
levels of FT3 and FT4 (r = −0.543 and −0.504, p < 0.01,
respectively) in the HO group and positively correlated with
TSH levels in the HO (r = 0.461, p < 0.01) and SHO (r =
0.264, p < 0.05) groups. The plasma Hcy levels were nega-
tively correlated with HDL-C in both the HO and SHO
Table 1 Characteristics and laboratory test findings for each group involved in this study
Variables Control group (n = 94) SHO (n = 91) HO (n = 73) p-value
Sex, M/F 10/84 9/82 8/65 0.973
Age, years 46.78 ± 11.22 45.96 ± 13.97 43.07 ± 13.55 0.077
BMI, km/m2 24.15 ± 3.25 24.57 ± 3.31 24.63 ± 3.19 0.990
CHOL, mmol/l 5.00 ± 1.00 5.09 ± 1.21 5.98 ± 1.67†‡ <0.001**
HDL-C, mmol/l 1.47 ± 0.30 1.47 ± 0.33 1.62 ± 0.40†‡ 0.027*
LDL-C, mmol/l 2.89 ± 0.81 3.03 ± 0.95 3.47 ± 1.21†‡ 0.001**
TG, mmol/l 1.12 (0.79–1.69) 1.16 (0.78–1.78) 1.28 (0.88–1.76) 0.708
Apo A-I, g/l 1.35 ± 0.27 1.34 ± 0.28 1.49 ± 0.38†‡ 0.005**
Apo B, g/l 0.89 ± 0.24 0.92 ± 0.26 1.01 ± 0.34†‡ 0.007**
Hcy, μmol/l 13.00 (10.75–15.00) 14.00 (12.00–17.00)† 15.00 (13.00–21.50)†‡ <0.001**
Summary of the clinical characteristics and laboratory test results of the study participants (94 controls, 91 patients with SHO and 73 patients with HO). The data are
expressed as means ± SDs unless otherwise indicated. TG and Hcy levels are presented as medians (25th and 75th percentiles). BMI body mass index, CHOL
total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, Apo A-I apolipoprotein A-I, Apo B apolipoprotein B, Hcy
homocysteine. Comparisons among groups were performed using aone-way ANOVA test. Because TG and Hcy levels did not follow a normal distribution, comparisons
between groups were performed using the Mann–Whitney U test or Kruskal–Wallis H test. *p < 0.05, **p < 0.01, significantly different among the three groups;
†p < 0.05, significantly different compared with the control group; ‡p < 0.05, significantly different compared with the SHO group
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groups (r= −0.375 and −0.356, all p < 0.01, respectively).
Additionally, the Hcy levels were negatively corre-
lated with Apo A- I in the HO, SHO and control
groups (r = −0.320, −0.337 and −0.317; all p < 0.01,
respectively).
Discussion
HO and SHO are both associated with atherosclerosis
[2, 3]. A major factor that contributes to this condition
is dyslipidemia, which is observed in these patients
[4, 5]. The relationship between coronary artery disease
and low levels of plasma HDL-C has been demonstrated in
earlier, prospective studies [7, 8]. Apo A-I is a major protein
component of HDL-C and may exert anti-atherogenic ef-
fects through several mechanisms. Reduced levels HDL-C
and Apo A-I increase the risk of cardiovascular disease.
However, some studies and our present findings indicate
that HDL-C and Apo A-I levels are increased in patients
with HO or SHO and did not show an effect on anti-
atherosclerotic function. HHcy is an independent risk factor
for cardiovascular disease [13, 14]. HHcy increases cardio-
vascular disease via various mechanisms, including endo-
thelial dysfunction, oxidative stress, endoplasmic reticulum
stress, smooth muscle cell proliferation and platelet aggre-
gation [26–29]. Our previous study demonstrated that
HHcy induced insulin resistance in patients with HO or
SHO [15] and impaired coronary artery endothelial func-
tion in patients with hypertension or hypertriglyceridemia
[16, 17]. Some studies have shown that Hcy levels are
increased in hypothyroid patients [11, 12]. Our previous
study demonstrated that HHcy might contribute to athero-
genesis by enhancing the responsiveness of monocytes to
inflammatory stimuli and thereby promoting insulin resist-
ance via the induction of endoplasmic reticulum stress in
adipose tissue along with impairing coronary artery
endothelial function [16, 17]. HHcy can inhibit reverse
cholesterol transport by reducing circulating HDL via
the inhibition of Apo A-I protein synthesis, resulting in
an increased risk of atherosclerosis [30, 31]. Concurrently,
other studies reported that HHcy impaired the antioxidant
ability of Apo A-I and HDL-C [22]. In this present study,
we provide for the first time evidence for a negative
correlation between Hcy and Apo A-I in patients with
HO or SHO.
We observed that subjects in the control and SHO
groups had lower levels of CHOL, HDL-C, LDL-C, Apo
A-I and Apo B than individuals in the HO group. By
altering lipid metabolism, HO accelerates the process of
atherogenesis and increases cardiovascular risk. Overt
HO is characterized by hypercholesterolemia and a marked
increase in LDL-C and Apo B because of decreased frac-
tional clearance of LDL-C, which is a consequence of fewer
LDL-C receptors in the liver. Apo A-I, a major protein
component of HDL, is a major contributor to the anti-
atherosclerotic effects. Levels of HDL-C are elevated in HO
because of decreased CETP and hepatic lipase activity,
which are both enzymes regulated by thyroid hormones
[32]. Increased levels of CHOL, LDL-C and Apo B are
linked to atherosclerosis. Hcy was significantly higher in the
HO group than in the SHO and control groups. Our find-
ings are consistent with those of previous studies [11, 12].
Hcy is a sulfur-containing amino acid that is formed during
methionine metabolism. Intensive studies have identified
HHcy as an independent risk factor for atherosclerosis
[13, 14]. Our previous study demonstrated that HHcy
may contribute to atherogenesis by enhancing the re-
sponsiveness of monocytes to inflammatory stimuli and
promoting leukocyte recruitment into atherosclerotic
plaques [33]. A portion of Hcy is converted to HcyT by
Fig. 2 Plasma levels of Hcy in the study subjects. n = 94 in the control
group; n = 91 in the SHO group and n = 73 in the HO group
Fig. 1 Plasma levels of Apo A-I in the study subjects. n = 94 in the
control group; n = 91 in the SHO group and n = 73 in the HO group
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methionyl-tRNA synthetase. Indeed, levels of plasma
HcyT are increased in humans with HHcy caused by muta-
tions in the cystathionine β-synthase or 5,10-methylene-tet-
rahydrofolate reductase genes [21]. HcyT, a cyclic thioester,
forms an isopeptide bond with lysine residues of proteins,
which is known as N-homocysteinylation. The N-homocys-
teinylation of proteins can lead to the loss or modulation of
protein function. In addition, N-homocysteinylated proteins
may cause atherosclerosis via cell death, inflammation, and
adaptive immune responses. N-homocysteinylated Apo A-I
is present in normal human serum at a proportion of 1.0–
7.4 % of N-Hcy-Apo A-I among total Apo A-I [11]. With
increasing levels of Hcy in patients with HO or SHO, levels
of N-Hcy-Apo A-I may be increased. A recent study found
that N-Hcy-Apo A-I promotes LDL-C oxidation, and
HcyT-treated HDL-C also loses its antioxidant activity.
Therefore, increased levels of Apo A-I and HDL-C do not
affect antioxidant ability because N-homocysteinylation of
Apo A-I impairs this function [22]. Dyslipidemia and HHcy
may both be associated with endothelial dysfunction and
cardiovascular disease.
To investigate the association between HHcy and blood
lipid indexes, we performed a subgroup analysis. Each
patient group was subdivided into two subgroups accord-
ing to the plasma Hcy levels. Similar to other studies, the
levels of CHOL, HDL-C, LDL-C and Apo A-I in the HO
group were higher than those in the SHO and control
groups for patients with normal plasma levels of Hcy.
However, among the three hyperhomocysteinemic sub-
groups, the differences in HDL-C and Apo A-I values
were not significant, and Apo A-I only showed a differ-
ence between the H-HO and H-control groups, with
lower levels in the latter group. Levels of HDL-C and
Apo A-I were significantly lower in the hyperhomocysteine-
mic subgroups compared with the subgroups of patients
with HO or SHO and normal plasma Hcy levels. Apo A-I
and HDL-C can reduce the risk of cardiovascular disease
by promoting reverse cholesterol transport and modulating
inflammation [9, 10]. Hcy can inhibit reverse cholesterol
transport by reducing circulating HDL-C via the inhibition
of the expression and protein synthesis of Apo A-I and the
enhancement of HDL-C clearance in an animal model
Table 2 Comparison of characteristics and the laboratory test findings for the subgroups of each group













Sex, M/F 6/70 4/14 6/53 3/29 1/36 7/29
Age, years 46.42 ± 11.21 48.28 ± 11.46 45.41 ± 13.98 46.97 ± 14.10 41.73 ± 10.48 44.44 ± 16.16
BMI, km/m2 23.89 ± 3.09 25.21 ± 3.77 24.22 ± 3.35 25.19 ± 3.19 23.96 ± 3.32 25.32 ± 2.94
CHOL, mmol/l 4.99 ± 1.03 5.03 ± 0.90 4.99 ± 0.85 5.26 ± 1.69 5.73 ± 1.15cd 6.24 ± 2.06ab
HDL-C, mmol/l 1.48 ± 0.31 1.41 ± 0.25 1.54 ± 0.32 1.35 ± 0.31** 1.79 ± 0.34 cd 1.44 ± 0.37**
LDL-C, mmol/l 2.87 ± 0.82 2.97 ± 0.76 2.91 ± 0.72 3.25 ± 1.26 3.36 ± 0.94 cd 3.58 ± 1.43
TG, mmol/l 1.18 (0.78–1.72) 1.11 (0.94–1.55) 1.20 (0.77–1.79) 1.10 (0.79–1.64) 1.03 (0.83–1.63) 1.39 (0.92–2.51)
ApoA-I, g/l 1.38 ± 0.28 1.20 ± 0.17* 1.39 ± 0.27 1.25 ± 0.27* 1.59 ± 0.38 cd 1.39 ± 0.35a*
ApoB, g/l 0.88 ± 0.25 0.89 ± 0.21 0.89 ± 0.22 0.96 ± 0.32 0.99 ± 0.29 c 1.03 ± 0.39
To investigate the association among patient characteristics, blood lipid indexes and HHcy, we subdivided each group of patients into two groups according to the plasma
Hcy levels. In the HO group, patients with a plasma level of Hcy > 15 μmol/l were termed the H-HO group (n= 36), while other patients were included in the N-HO group
(n= 37). Similarly, we subdivided the SHO group into H-SHO (n= 32) and N-SHO (n= 59) subgroups and subdivided the control group into the H-control (n= 18) and N-
control (n= 76) groups. The data are expressed as the means ± SDs unless otherwise indicated. TG is presented as medians (25th and 75th percentiles). Comparisons among
groups were performed with independent-samples or one-way ANOVA tests. Because TG did not follow a normal distribution, between-group comparisons were performed
using the Mann–Whitney U test or Kruskal–Wallis H test. *p < 0.05, **p < 0.01 indicate a significant difference between two subgroups; ap < 0.05, significantly
different compared with the H-control group; bp < 0.05, significantly different compared with the H-SHO group; cp < 0.05, significantly different compared with
the N-control group; dp < 0.05, significantly different compared with the N-SHO group
Fig. 3 Apo A-I values in the study subgroups. n= 76 in the N-control
group (control subjects with a plasma level of Hcy ≤ 15 μmol/l); n= 18
in the H-control group (control subjects with a plasma level of Hcy >
15 μmol/l); n= 59 in the N-SHO group (patients with SHO and a plasma
level of Hcy ≤ 15 μmol/l); n= 32 in the H-SHO group (patients with SHO
and a plasma level of Hcy > 15 μmol/l); n = 37 in the N-HO group
(patients with HO and a plasma level of Hcy ≤ 15 μmol/l); n = 36 in
the H-HO group (patients with HO and a plasma level of Hcy > 15 μmol/l)
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[30, 31]. This finding suggests that Hcy inhibited the
expression of Apo A-I and HDL-C in patients with HO
or SHO, which could increase the risk of cardiovascular
disease.
Our study showed that Hcy was negatively correlated
with levels of FT3 and FT4 in the HO group and posi-
tively correlated with levels of TSH in the SHO and HO
groups. Several other studies have proposed that HO
reduces hepatic levels of the enzymes involved in Hcy
metabolism. This hypothesis has been supported by the
finding that HO and SHO are associated with alterations
in plasma levels of Hcy [34, 35]. We observed that plasma
levels of Hcy were negatively correlated with those of
HDL-C in the HO and SHO groups and were negatively
correlated with levels of Apo A-I among the three groups.
With an increased level of Hcy, there was a concurrent
reduction in the levels of HDL-C and Apo A-I. Similar
correlations have been reported in other diseases [30, 31].
To the best of our knowledge, we have established for the
first time that plasma Hcy levels show a significant, nega-
tive correlation with Apo A-I concentrations in patients
with HO or SHO. Our findings suggest that HHcy impairs
the antioxidant ability of Apo A-I and inhibits the expres-
sion of Apo A-I and HDL-C; these events are associated
with an increased risk of cardiovascular disease in patients
with HO or SHO.
Conclusions
Plasma Hcy levels were significantly increased in patients
with HO or SHO. These increased levels of Hcy may im-
pair cardiovascular function by impairing the antioxidant
ability of Apo A-I and inhibiting the expression of Apo A-I
and HDL-C. Our findings suggest that HHcy may increase
cardiovascular risk via multiple effects, especially through a
mechanism that can induce dyslipidemia in patients with
HO and SHO. Thus, our findings provide new insights
into the pathogenesis of HO- and SHO-induced meta-
bolic disorders.
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